Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

Chin-Chou Huang; Min-Ji Charng

doi:10.2147/TCRM.S193971

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

Ther Clin Risk Manag. 2019 Oct 15:15:1209-1216. doi: 10.2147/TCRM.S193971. eCollection 2019.

Authors

Chin-Chou Huang^{1

2

3

4

5}, Min-Ji Charng^{2

3}

Affiliations

¹ Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
² Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
³ Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
⁴ Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan.
⁵ Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan.

Abstract

Evolocumab, which can lower low-density lipoprotein (LDL) cholesterol levels by approximately 60% and prevent cardiovascular events in patients with cardiovascular disease, is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Some studies have investigated its efficacy and safety in the treatment of the homozygous form of familial hypercholesterolemia (HoFH), and others have focused on its efficacy and safety in Asians with high cardiovascular risk. Although no direct evolocumab clinical trials have been conducted in Chinese HoFH patients, its efficacy and safety in the Chinese population should be similar to those in other ethnic groups.

Keywords: Chinese; evolocumab; homozygous familial hypercholesterolemia; low-density lipoprotein; proprotein convertase subtilisin/kexin type 9.

Publication types

Review

Grants and funding

This work was funded by Taiwan’s National Ministry of Science and Technology (Grant number, MOST105-2314-B-075-040) and by Taipei Veterans General Hospital (Grant numbers, V105C-208 and V107C-078).